Savara (NASDAQ:SVRA) Releases Earnings Results, Misses Estimates By $0.01 EPS

Savara (NASDAQ:SVRA) issued its quarterly earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), FiscalAI reports.

Savara Trading Down 0.8%

Shares of NASDAQ:SVRA traded down $0.04 during mid-day trading on Tuesday, hitting $5.08. The company had a trading volume of 720,880 shares, compared to its average volume of 1,515,326. The firm has a fifty day moving average price of $5.40 and a 200 day moving average price of $5.46. The company has a market capitalization of $1.04 billion, a PE ratio of -9.58 and a beta of 0.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85. Savara has a one year low of $1.89 and a one year high of $7.01.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SVRA shares. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Oppenheimer started coverage on shares of Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Savara in a research note on Monday, March 16th. Finally, William Blair set a $10.00 price objective on shares of Savara in a research note on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.13.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently bought and sold shares of the business. VR Adviser LLC grew its stake in shares of Savara by 8.4% in the 4th quarter. VR Adviser LLC now owns 13,740,375 shares of the company’s stock worth $82,854,000 after acquiring an additional 1,059,332 shares in the last quarter. Nantahala Capital Management LLC grew its stake in shares of Savara by 5.4% in the 3rd quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock worth $31,328,000 after acquiring an additional 450,000 shares in the last quarter. RTW Investments LP bought a new stake in shares of Savara in the 4th quarter worth $35,893,000. Marshall Wace LLP bought a new stake in shares of Savara in the 4th quarter worth $27,496,000. Finally, State Street Corp grew its stake in shares of Savara by 83.6% in the 4th quarter. State Street Corp now owns 4,333,022 shares of the company’s stock worth $26,128,000 after acquiring an additional 1,973,164 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.